News
Precision BioSciences (DTIL) announced that the FDA has granted fast track designation for PBGENE-HBV, the company’s lead wholly owned in vivo ...
Precision BioSciences (DTIL) announced the presentation of preclinical data for its PBGENE-DMD development program for the treatment of Duchenne muscular dystrophy during an oral presentation at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback